Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Lilly peglispro delay may be boon for its biosimilar
Lilly peglispro delay may be boon for its biosimilar
Lilly peglispro delay may be boon for its biosimilar
Submitted by
admin
on February 23, 2015 - 5:54pm
Source:
Medical Marketing and Media
News Tags:
Eli Lilly
Peglispro
diabetes
basal insulin
biosimilars
Sanofi
Lantus
Headline:
Lilly peglispro delay may be boon for its biosimilar
Do Not Allow Advertisers to Use My Personal information
